An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Administration of infliximab to patients with acute severe ulcerative colitis (ASUC) (rescue therapy) can reduce the rate of early colectomy (within 12 months), but long-term rates of colectomy are the same as those of the pre-biologic era for these patients. The half-life of infliximab is shorter in patients with ASUC than in patients with non-severe UC, so more frequent dosing might be required to produce a therapeutic effect.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Gastroenterol. Hepatol.

Title: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

ISSN (Electronic): 1542-7714

ISSN (Print): 1542-3565

Publication date (Electronic): Feb 2015

Volume: 13

Issue: 2

Affiliations

[1 ] Centre for Colorectal Disease, St Vincent's University Hospital and School of Medicine and Medical Science, University College Dublin, Dublin, Ireland. Electronic address: gibsond@tcd.ie.

[2 ] Centre for Colorectal Disease, St Vincent's University Hospital and School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.

Article

Publisher Item ID: S1542-3565(14)01086-6

DOI: 10.1016/j.cgh.2014.07.041

PubMed ID: 25086187

SO-VID: 1d555ddd-194f-4698-8374-29c4727a1a98

History

Keywords: Accelerated Induction,Infliximab,Ulcerative Colitis

Data availability:

Keywords: Accelerated Induction, Infliximab, Ulcerative Colitis

Comments

Comment on this article

scite_

Cited by 63

See all cited by